GlassScriptPhysician profile
Atisha Patel Manhas
NPI 1508001199
$4,460.63
in general payments reported to CMS, 2019-2025
51 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.54 · 2021: $159 · 2022: $147 · 2023: $285 · 2024: $1,223 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,391 · Long Term Medical Supply Or Device Loan: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.97 |
| Long Term Medical Supply Or Device Loan | $697.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,088.44 | 2022-2025 | |
| Janssen Biotech, INC. | $542.60 | 2024-2025 | Erleada, Carvykti, Rybrevant |
| Gilead Sciences, INC. | $279.75 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $260.27 | 2023-2025 | Opdivo, Eliquis |
| Tempus Ai, INC | $209.61 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $197.75 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $160.47 | 2024-2025 | |
| Genzyme Corporation | $152.31 | 2024-2025 | |
| Pfizer INC. | $145.70 | 2022-2025 | |
| Kite Pharma, INC. | $123.82 | 2022-2025 | Yescarta |
| Glaxosmithkline, LLC. | $117.55 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $100.08 | 2023-2025 | Imfinzi, Enhertu |
| Lilly USA, LLC | $82.14 | 2021 | |
| Incyte Corporation | $76.05 | 2024-2025 | Jakafi |
| Astellas Pharma US INC | $66.01 | 2024-2025 | Xtandi |
Show all 45 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atisha Manhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.